Table 1.

Delphi questionnaire consensus report

Statement		Respondents who agreed (%)
1	I feel that to implement an antiangiogenic therapy is important to know the infiltration of the tumour into adjacent structures such as:
	i. Pleura	0.00
	ii. Chest wall	0.00
	iii. Bone	0.00
	iv. Bronchi	83.33
	v. Mediastinum	100.00
	vi. Oesophagus	66.67
	vii. Trachea	66.67
	viii. Carina	83.33
	ix. Large vessels	100.00
2	To evaluate vessels infiltration by CT scan in patients with NSCLC, I think it is sufficient to have the resolution given by a thickness of:
	i. 5 mm	0.00
	ii. 3 mm	83.33
	iii. 1.5 mm	83.33
3	In the evaluation of treatment with antiangiogenic therapy I consider essential to know whether or not a thrombus is present	100
4	In the absence of infiltration of vessels, I think that tumour site (central or peripheral) is relevant for treatment	66.67
5	I think that cavitation is a contraindication to antiangiogenic therapy	66.67
6	I believe that the compression of a major vascular structure listed below by a secondary lymphadenopathy is a contraindication for antiangiogenic therapy
	i. Vena cava	33.33
	ii. Aorta	16.67
	iii. Pulmonary arteries	33.33
	iv. Pulmonary veins	33.33
7	I think that proximity of the disease to a large vessel is not a contraindication to antiangiogenic therapy	66.67
8	I believe that the alteration of the lung parenchyma may be a risk factor for bleeding if it is:
	i. Fibrosis	0.00
	ii. Bronchiectasis	50.00
	iii. Emphysema	0.00
	iv. Endobronchial tumour extension	83.33
	v. Pleural effusion	0.00
9	In evaluating the feasibility of antiangiogenic therapy I think it is essential to know the presence of deep venous thrombosis requiring antiplatelet therapy	83.33
10	I think that pleural effusion is always a contraindication to antiangiogenic therapy	0
11	I think that pleural effusion is a contraindication to antiangiogenic therapy only if it is haemorrhagic	50
12	I think pleural effusion is a contraindication to antiangiogenic therapy only after pleurodesis.	0
13	For the chest tumour site, I consider that, to be useful to clinical practice, a structured report should include at least:
	i. Cavitation	100.00
	ii. Vascular infiltration	100.00
	iii. Fistulas	83.33
	iv. Endobronchial growth	100.00
	v. Lymphangitis	66.67
	vi. Margins	83.33
	vii. Thromboembolism	100.00
14	For the extrathoracic tumour site, I consider that, to be useful to clinical practice, a structured report should include at least:
	i. Fistulas	66.67
	ii. Aneurysms	100.00
	iii. Diverticula	66.67
	iv. Extra-thoracic bleeding sites	100.00
	v. Brain metastases	100.00
	vi. Thrombi	100.00